Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017)

Published:2019-07 Issue:3 Volume:94 Page:304-313
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Pfaller Michael A.,Flamm Robert K.,Duncan Leonard R.,Shortridge Dee,Smart Jennifer I.,Hamed Kamal A.,Mendes Rodrigo E.,Sader Helio S.

Funder

Basilea Pharmaceutica International Ltd.

Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference33 articles.

1. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection;Ammerlaan;Clin Infect Dis,2013

2. Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used;Anderegg;J Clin Microbiol,2004

3. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia;Awad;Clin Infect Dis,2014

4. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002);Biedenbach;Diagn Microbiol Infect Dis,2004

5. Incentives for new antibiotics: the options market for antibiotics (OMA) model;Brogan;Glob Health,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended;Journal of Clinical Medicine;2023-12-14

2. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia;New England Journal of Medicine;2023-10-12

3. Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital;International Journal of Antimicrobial Agents;2023-08

4. Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Host, Pathogen, and Treatment;Antibiotics;2023-02-24

5. Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020;Diagnostic Microbiology and Infectious Disease;2022-07